Mantle cell lymphoma trials in France

In France 17 Also abroad 150

17 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Where
Lille, Montpellier, Nantes, Paris
Age
18 years and over
People
182 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06084936
Phase 1Taking people
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Where
Lille, Paris
Age
18 years and over
People
215 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07101328 · EU 2025-524180-20-00
Phase 1Taking people
A Study of ARC-02 in B-cell NHL
Where
Creteil Cedex, Lille, Nantes, Pierre-Bénite, Villejuif Cedex
Age
18 years and over
People
140 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT07691606 · EU 2026-525606-35-00
Phase 3Taking people
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Where
Montpellier Cedex 5, Nantes, Pierre-Bénite, Tours Cedex 9
Age
18 years and over
People
300 worldwide
Run by
BeOne Medicines
See details and how to joinNCT06742996 · EU 2024-515593-27-00
Phase 1/2Taking people
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Where
Clermont-Ferrand, Montpellier Cedex 5, Paris, Saint-Cloud, Villejuif
Age
18 years and over
People
408 worldwide
Run by
AstraZeneca
See details and how to joinNCT06564038 · EU 2024-515034-33-00
Phase 1/2Taking people
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Where
Dijon, Montpellier Cedex 5, Toulouse Cedex 9
Age
18 years and over
People
258 worldwide
Run by
BeOne Medicines
See details and how to joinNCT06697184 · EU 2024-518829-15-00
Phase 1/2Taking people
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Where
Bordeaux, ClermontFerrand, Créteil, Lille, Lyon, Marseille, Montpellier, Paris, Rouen
Age
18 years and over
People
689 worldwide
Run by
BeOne Medicines
See details and how to joinNCT05006716 · EU 2022-502157-33-00
Phase 1/2Taking people
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Where
Pessac, Villejuif
Age
18 years and over
People
174 worldwide
Run by
AstraZeneca
See details and how to joinNCT06542250
Phase 3Taking people
A Study to Compare the Efficacy and Safety of Glofitamab as a Single Agent Versus Investigator’s Choice in Patients with Relapsed/Refractory Mantle Cell Lymphoma
Where
Lille Cedex, Montpellier Cedex 5, Nantes, Paris, Saint-Cloud
Age
18 years and over
People
39 worldwide
Run by
F. Hoffmann-La Roche AG
See details and how to join2023-503206-37-00 · EU 2023-503206-37-00
Phase 1Taking people
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Where
Bordeaux, Marseille, Nantes
Age
18 years and over
People
85 worldwide
Run by
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
See details and how to joinNCT06980116 · EU 2024-516869-36-00
Phase 2Taking people
Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma
Where
Créteil, Dijon, Lille, Marseille, Montpellier, Nantes, Pierre-Bénite, Reims, Rennes, Rouen, Saint-Cloud, Strasbourg
Age
18 years to 79 years
People
100 worldwide
Run by
The Lymphoma Academic Research Organisation
See details and how to joinNCT06558604
Phase 1Taking people
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Where
Angers, Bobigny, Nantes, Pessac, Poitiers, Saint-Cloud, Vandœuvre-lès-Nancy
Age
18 years and over
People
572 worldwide
Run by
Nurix Therapeutics, Inc.
See details and how to joinNCT05131022 · EU 2023-510541-25-00
Phase 2/3Taking people
A phase II, multicenter, open-label study evaluating Glofitamab in combination with Venetoclax plus Zanubrutinib or Venetoclax alone in subjects with untreated or relapsed/refractory high-risk mantle-cell lymphoma
Where
Creteil Cedex, Dijon, Lille Cedex, Marseille, Montpellier Cedex 5, Nantes, Pierre-Bénite, Reims, Rennes, Rouen, Saint-Cloud, Strasbourg Cedex
Age
18 years and over
People
100 worldwide
Run by
Lymphoma Academic Research Organisation
See details and how to join2023-506706-40-00 · EU 2023-506706-40-00
Phase 1Taking people
Study of SGR-1505 in Mature B-Cell Neoplasms
Where
Creteil Cedex, Villejuif
Age
18 years and over
People
98 worldwide
Run by
Schrödinger, Inc.
See details and how to joinNCT05544019 · EU 2023-505204-34-00
Phase 3Taking people
A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
Where
Caen Cedex 9, Clermont-Ferrand, Le Mans Cedex 9, Lille Cedex, Limoges Cedex 1, Lyon, Nantes Cedex 2, Nice Cedex 2, Paris, Pessac, Rennes Cedex 9, Saint-Quentin, Tours
Age
60 years and over
People
476 worldwide
Run by
InnoCare Pharma Inc.
See details and how to joinNCT06363994 · EU 2025-524241-27-00
Phase 2Taking people
CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma
Where
Clermont-Ferrand, Creteil Cedex, Dijon, Lille, Marseille, Montpellier Cedex 5, Nantes, Paris, Pessac, Pierre-Bénite, Rennes
Age
18 years to 75 years
People
150 worldwide
Run by
Christian Schmidt, MD
See details and how to joinNCT06482684 · EU 2022-502405-15-01
No phaseTaking people
REal World Data in LYmphoma and Survival in Adults
Where
Arras, Besançon, Bordeaux, Bourgoin, Caen, Chambéry, Clermont-Ferrand, Créteil, Dijon, Dunkirk, Grenoble, La Roche-sur-Yon, La Tronche, Le Mans, Libourne, Lille, Limoges, Lyon, Montpellier, Mulhouse, Nantes, Niort, Paris, Pessac, Pierre-Bénite, Poitiers, Rennes, Roubaix, Rouen, Saint-Brieuc, Saint-Cloud, Saint-Priest-en-Jarez, Strasbourg, Toulouse, Vannes
Age
18 years and over
People
6,000
Run by
Hospices Civils de Lyon
See details and how to joinNCT03869619